Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21479474 | 0.87 | EIF4A3 (0.37) | EIF4A3GABRA1GABRB2LMNATRPA1 | |
| SCHEMBL22168395 | 0.85 | EIF4A3 (0.36) | EIF4A3GABRA1GABRB2LMNATRPA1 | |
| SCHEMBL12144344 | 0.80 | HTR2A (0.36) | EIF4A3GABRA1GABRB2 | |
| SCHEMBL12360643 | 0.80 | HDAC4 (0.38) | EIF4A3GABRA1GABRB2LMNA | |
| SCHEMBL8134770 | 0.80 | CES2 (0.41) | EIF4A3GABRA1GABRB2LMNATRPA1 | |
| SCHEMBL20632409 | 0.79 | HDAC1 (0.39) | EIF4A3HDAC1HDAC6LMNAPTGS1 | |
| SCHEMBL19654073 | 0.79 | ADRB2 (0.36) | HDAC1HDAC6ADRB2 | |
| SCHEMBL12563296 | 0.79 | ADRB2 (0.36) | HDAC1HDAC6ADRB2 | |
| SCHEMBL7732357 | 0.79 | HDAC1 (0.34) | HDAC1HDAC6 | |
| SCHEMBL19654075 | 0.79 | ADRB2 (0.36) | HDAC1HDAC6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOUTHERN RES INST (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2351741-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING NITROGEN-CONTAINING HETEROCYCLIC RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110147655-A1 | POLAR NEMATIC COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2011-06-23 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20100317677-A1 | Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | EIF4A3 3219/4885GABRA1 546/4885GABRB2 80/4885 |
| US-11718593-B2 | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases | SMN1; SMN2, TDP2, TDP1 | EIF4A3 2300/4885GABRA1 1342/4885GABRB2 544/4885 |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | EIF4A3 3140/4885GABRA1 339/4885GABRB2 738/4885 |
| US-20100317677-A1 | Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity | RNASEL, RNASE1, RNASEH1 | EIF4A3 1245/4885GABRA1 4825/4885GABRB2 4840/4885 |
| US-20110263564-A1 | PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT6 | EIF4A3 4527/4885GABRA1 3150/4885GABRB2 2417/4885 |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | EIF4A3 3642/4885GABRA1 542/4885GABRB2 140/4885 |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | PNMT, HTR5A, HNMT | EIF4A3 3896/4885GABRA1 2436/4885GABRB2 2845/4885 |
| US-20110077248-A1 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | EIF4A3 3171/4885GABRA1 3401/4885GABRB2 2269/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | EIF4A3 4395/4885GABRA1 563/4885GABRB2 275/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | EIF4A3 3798/4885GABRA1 971/4885GABRB2 289/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | EIF4A3 782/4885GABRA1 3982/4885GABRB2 4176/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | EIF4A3 3506/4885GABRA1 1533/4885GABRB2 498/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | EIF4A3 3219/4885GABRA1 546/4885GABRB2 80/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | EIF4A3 1554/4885GABRA1 2605/4885GABRB2 1825/4885 |
| US-20230286933-A1 | 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, TDP2, TDP1 | EIF4A3 2300/4885GABRA1 1342/4885GABRB2 544/4885 |
| US-20110147655-A1 | POLAR NEMATIC COMPOUNDS | BCOR, LATS1, LATS2 | EIF4A3 2113/4885GABRA1 1286/4885GABRB2 1313/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | EIF4A3 634/4885GABRA1 2672/4885GABRB2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.